Adma Biologics, Inc. ADMA
We take great care to ensure that the data presented and summarized in this overview for ADMA BIOLOGICS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ADMA
View all-
Black Rock Inc. New York, NY18.2MShares$193 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$135 Million0.0% of portfolio
-
State Street Corp Boston, MA10.6MShares$112 Million0.0% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL10.5MShares$111 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA7.8MShares$83 Million0.01% of portfolio
-
American Century Companies Inc Kansas City, MO7.13MShares$75.8 Million0.03% of portfolio
-
Perceptive Advisors LLC New York, NY6.43MShares$68.4 Million0.89% of portfolio
-
Awm Investment Company, Inc. New York, NY5.71MShares$60.7 Million5.62% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.38MShares$57.2 Million0.03% of portfolio
-
Geode Capital Management, LLC Boston, MA4.81MShares$51.1 Million0.0% of portfolio
Latest Institutional Activity in ADMA
Top Purchases
Top Sells
About ADMA
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
Insider Transactions at ADMA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2024
|
Adam S Grossman President,CEO, and Interim CFO |
SELL
Open market or private sale
|
Direct |
100,000
-4.58%
|
$1,000,000
$10.72 P/Share
|
|
Jun 14
2024
|
Adam S Grossman President,CEO, and Interim CFO |
SELL
Bona fide gift
|
Direct |
10,000
-0.46%
|
-
|
|
Jun 14
2024
|
Adam S Grossman President,CEO, and Interim CFO |
SELL
Other acquisition or disposition
|
Direct |
460,000
-17.35%
|
$1,380,000
$3.21 P/Share
|
|
Apr 01
2024
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
BUY
Grant, award, or other acquisition
|
Direct |
192,320
+38.71%
|
-
|
|
Mar 31
2024
|
Adam S Grossman President,CEO, and Interim CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
21,752
-0.81%
|
$130,512
$6.6 P/Share
|
|
Mar 31
2024
|
Kaitlin M. Kestenberg Messina COO and SVP, Compliance |
SELL
Payment of exercise price or tax liability
|
Direct |
2,085
-1.82%
|
$12,510
$6.6 P/Share
|
|
Mar 19
2024
|
Steve Elms |
SELL
Open market or private sale
|
Indirect |
411,829
-16.29%
|
$2,470,974
$6.08 P/Share
|
|
Mar 18
2024
|
Steve Elms |
SELL
Open market or private sale
|
Indirect |
49,887
-1.94%
|
$299,322
$6.01 P/Share
|
|
Mar 15
2024
|
Steve Elms |
SELL
Open market or private sale
|
Indirect |
183,008
-6.63%
|
$1,098,048
$6.01 P/Share
|
|
Mar 14
2024
|
Steve Elms |
SELL
Open market or private sale
|
Indirect |
448,276
-13.97%
|
$2,689,656
$6.05 P/Share
|
|
Mar 13
2024
|
Steve Elms |
SELL
Open market or private sale
|
Indirect |
407,000
-11.26%
|
$2,442,000
$6.21 P/Share
|
|
Mar 07
2024
|
Adam S Grossman President,CEO, and Interim CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
28,763
-1.06%
|
$172,578
$6.16 P/Share
|
|
Mar 07
2024
|
Brian Lenz EVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,965
-2.36%
|
$101,790
$6.16 P/Share
|
|
Mar 06
2024
|
Adam S Grossman President,CEO, and Interim CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
55,003
-2.0%
|
$330,018
$6.12 P/Share
|
|
Mar 06
2024
|
Brian Lenz EVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,677
-2.26%
|
$100,062
$6.12 P/Share
|
|
Feb 29
2024
|
Brian Lenz EVP, CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,935
-0.67%
|
$24,675
$5.36 P/Share
|
|
Feb 29
2024
|
Adam S Grossman President,CEO, and Interim CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,588
-0.35%
|
$47,940
$5.36 P/Share
|
|
Feb 26
2024
|
Steve Elms |
BUY
Grant, award, or other acquisition
|
Direct |
24,040
+23.92%
|
-
|
|
Feb 26
2024
|
Bryant Fong |
BUY
Grant, award, or other acquisition
|
Direct |
24,040
+22.26%
|
-
|
|
Feb 26
2024
|
Lawrence P. Guiheen |
BUY
Grant, award, or other acquisition
|
Direct |
24,040
+13.51%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 894K shares |
|---|---|
| Open market or private purchase | 155K shares |
| Exercise of conversion of derivative security | 2.91M shares |
| Open market or private sale | 4.18M shares |
|---|---|
| Payment of exercise price or tax liability | 2.52M shares |
| Bona fide gift | 10K shares |
| Other acquisition or disposition | 460K shares |